This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Musculoskeletal disease				
Osteoporosis	Calcium-sensing receptor (CaSR)	<p>An SAR study characterized a series of trisubstituted pyrimidines as CaSR antagonists that could be useful for treating osteoporosis.</p> <p><i>In vivo</i>, i.v. doses of the compounds rapidly and transiently stimulated parathyroid hormone (PTH) release, which is known to contribute to increased bone buildup. The compounds also displayed better potency and solubility than the parent compound. Next steps could include testing the compounds in mouse models of osteoporosis.</p> <p>JTT-305, a CaSR antagonist from Japan Tobacco Inc., is in Phase II testing in Japan and Phase I testing elsewhere to treat osteoporosis.</p> <p><i>SciBX</i> 2(5); doi:10.1038/scibx.2009.198 Published online Feb. 5, 2009</p>	Patent and licensing status unavailable	<p>Yang, W. <i>et al. J. Med. Chem.</i>; published online Jan. 15, 2009; doi:10.1021/jm801178c</p> <p>Contact: Wu Yang, Bristol-Myers Squibb Pharmaceutical Research Institute, Princeton, N.J. e-mail: Wu.Yang@bms.com</p>